GlassScriptPhysician profile
Caroline Bloss
NPI 1003582008
$6,978.87
in general payments reported to CMS, 2019-2025
36 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $1,964 · 2023: $1,797 · 2024: $1,814 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,339 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.67 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,422.04 | 2021-2025 | |
| Novo Nordisk INC | $1,264.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $675.07 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $459.85 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $393.52 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.16 | 2021-2024 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $252.79 | 2023-2025 | Veozah |
| Amgen INC. | $235.33 | 2021-2025 | Otezla, Repatha, Otezla |
| Bausch Health US, LLC | $196.85 | 2022-2025 | Wellbutrin, Aplenzin |
| Bayer Healthcare Pharmaceuticals INC. | $154.04 | 2022-2024 | |
| Exact Sciences Corporation | $148.73 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $112.14 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.82 | 2023-2024 | Cycloset, Xifaxan |
| Pfizer INC. | $92.59 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $92.38 | 2021-2023 | Belsomra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $89.57 | 2022 | |
| Lundbeck LLC | $88.32 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $86.74 | 2022-2023 | |
| Amarin Pharma, INC. | $85.35 | 2021-2022 | |
| Esperion Therapeutics, INC. | $79.67 | 2022-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $72.84 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $70.44 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $67.73 | 2024-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $49.45 | 2022 | |
| Medtronic, INC. | $48.59 | 2022 | |
| Paratek Pharmaceuticals, INC. | $48.39 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.43 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $35.77 | 2023 | Austedo Xr |
| Inspire Medical Systems, INC. | $22.10 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $17.96 | 2023 | Quviviq |
| Optinose US, INC. | $16.68 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.09 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $16.04 | 2024 | Leqembi |
| Sanofi-Aventis U.S. LLC | $15.83 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.07 | 2021 | |
| Daiichi Sankyo INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Bloss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.